Literature DB >> 27414954

Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy.

Gavin Rush1, Aoife O'Donovan2, Laura Nagle3, Catherine Conway3, AnnMaria McCrohan4, Cliona O'Farrelly5, James V Lucey3, Kevin M Malone4.   

Abstract

BACKGROUND: Immune system dysfunction is implicated in the pathophysiology of major depression, and is hypothesized to normalize with successful treatment. We aimed to investigate immune dysfunction in melancholic depression and its response to ECT.
METHODS: 55 melancholic depressed patients and 26 controls participated. 33 patients (60%) were referred for ECT. Blood samples were taken at baseline, one hour after the first ECT session, and 48h after ECT series completion.
RESULTS: At baseline, melancholic depressed patients had significantly higher levels of the pro-inflammatory cytokine IL-6, and lower levels of the regulatory cytokine TGF-β than controls. A significant surge in IL-6 levels was observed one hour after the first ECT session, but neither IL-6 nor TGF-β levels normalized after completion of ECT series. Seventy per cent (n=23) of ECT recipients showed clinical response and 42% (n=10) reached remission. Neither IL-6 nor TGF-β changes correlated with clinical improvement following ECT. No significant changes in IL-10, TNF-α and CRP levels were found in relation to melancholia or response to ECT. LIMITATIONS: As a naturalistic study, some potential confounders could not be eliminated or controlled, including medication use.
CONCLUSIONS: Melancholic depressed patients demonstrated a peripheral increase in IL-6 and reduction in TGF-β, which did not normalize despite clinical response to ECT. These findings may be consistent with emerging hypotheses of the role of inflammation in mediating neurotrophin expression. The implications of chronic inflammation in the melancholic depressed population for future medical health, particularly cardiovascular risk, are largely unknown and warrant further investigation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokines; Depression; Electroconvulsive therapy; Melancholic subtype; Psychoneuroimmunology

Mesh:

Substances:

Year:  2016        PMID: 27414954      PMCID: PMC5291160          DOI: 10.1016/j.jad.2016.06.035

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  98 in total

1.  Cytokine production and treatment response in major depressive disorder.

Authors:  S Lanquillon; J C Krieg; U Bening-Abu-Shach; H Vedder
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

2.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

3.  Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study.

Authors:  G Parker; K Roy; K Wilhelm; P Mitchell
Journal:  J Clin Psychiatry       Date:  2001-02       Impact factor: 4.384

4.  Antidepressant therapy and C-reactive protein levels.

Authors:  Sinead M O'Brien; Lucinda V Scott; Timothy G Dinan
Journal:  Br J Psychiatry       Date:  2006-05       Impact factor: 9.319

5.  Plasma noradrenaline response to electroconvulsive therapy in depressive illness.

Authors:  C B Kelly; S J Cooper
Journal:  Br J Psychiatry       Date:  1997-08       Impact factor: 9.319

6.  Differences and variability in plasma noradrenaline between depressive and anxiety disorders.

Authors:  C B Kelly; S J Cooper
Journal:  J Psychopharmacol       Date:  1998       Impact factor: 4.153

7.  The macrophage theory of depression.

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1991-08       Impact factor: 1.538

8.  Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression.

Authors:  I Goshen; T Kreisel; O Ben-Menachem-Zidon; T Licht; J Weidenfeld; T Ben-Hur; R Yirmiya
Journal:  Mol Psychiatry       Date:  2007-08-14       Impact factor: 15.992

9.  Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship?

Authors:  Mark Hamer; Gerard J Molloy; Cesar de Oliveira; Panayotes Demakakos
Journal:  Brain Behav Immun       Date:  2009-01-14       Impact factor: 7.217

10.  A detailed examination of cytokine abnormalities in Major Depressive Disorder.

Authors:  N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-03       Impact factor: 4.600

View more
  19 in total

1.  Anhedonia as a clinical correlate of inflammation in adolescents across psychiatric conditions.

Authors:  Rachel D Freed; Lushna M Mehra; Daniel Laor; Manishkumar Patel; Carmen M Alonso; Seunghee Kim-Schulze; Vilma Gabbay
Journal:  World J Biol Psychiatry       Date:  2018-08-16       Impact factor: 4.132

2.  Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways.

Authors:  Mengqi Yang; Ruili Dang; Pengfei Xu; Yujin Guo; Wenxiu Han; Dehua Liao; Pei Jiang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-25       Impact factor: 4.530

3.  Fish oil supplementation attenuates neuroinflammation and alleviates depressive-like behavior in rats submitted to repeated lipopolysaccharide.

Authors:  Ruili Dang; Xueyuan Zhou; Mimi Tang; Pengfei Xu; Xiaoxue Gong; Yuanyuan Liu; Hongxiao Jiao; Pei Jiang
Journal:  Eur J Nutr       Date:  2017-01-05       Impact factor: 5.614

Review 4.  Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.

Authors:  Milagros Rojas; Daniela Ariza; Ángel Ortega; Manuel E Riaño-Garzón; Mervin Chávez-Castillo; José Luis Pérez; Lorena Cudris-Torres; María Judith Bautista; Oscar Medina-Ortiz; Joselyn Rojas-Quintero; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

5.  Effects of Modified Electroconvulsive Therapy on Serum Cortisol, Nesfatin-1, and Pro-inflammatory Cytokine Levels in Elderly Patients With Treatment-Resistant Depression.

Authors:  Biao Dai; Xiaoping Wu; Fanfan Yan; Yang Chen; Yayun Xu; Qingrong Xia; Xulai Zhang; Xuefeng Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

6.  Low tumor necrosis factor-α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder.

Authors:  Annamari Sorri; Kaija Järventausta; Olli Kampman; Kai Lehtimäki; Minna Björkqvist; Kati Tuohimaa; Mari Hämäläinen; Eeva Moilanen; Esa Leinonen
Journal:  Brain Behav       Date:  2018-02-22       Impact factor: 2.708

Review 7.  Antidepressant Drugs and Physical Activity: A Possible Synergism in the Treatment of Major Depression?

Authors:  Claudia Savia Guerrera; Giovanna Furneri; Margherita Grasso; Giuseppe Caruso; Sabrina Castellano; Filippo Drago; Santo Di Nuovo; Filippo Caraci
Journal:  Front Psychol       Date:  2020-05-06

8.  Ω-3 fatty acids-supplementary in gestation alleviates neuroinflammation and modulates neurochemistry in rats.

Authors:  Mimi Tang; Ruili Dang; Shao Liu; Mengqi Zhang; Yi Zheng; Rui Yang; Tao Yin
Journal:  Lipids Health Dis       Date:  2018-11-03       Impact factor: 3.876

9.  Cross-National Variations in COVID-19 Mortality: The Role of Diet, Obesity and Depression.

Authors:  Ravi Philip Rajkumar
Journal:  Diseases       Date:  2021-05-06

10.  Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression.

Authors:  Jennifer L Kruse; Eliza Congdon; Richard Olmstead; Stephanie Njau; Elizabeth C Breen; Katherine L Narr; Randall Espinoza; Michael R Irwin
Journal:  J Clin Psychiatry       Date:  2018 Mar/Apr       Impact factor: 5.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.